FAIMS

Owlstone Medical Wins Contract from U.S. Department of Defense to Develop Handheld Breath Biopsy Device for Early Infectious Disease Detection

Retrieved on: 
Wednesday, May 17, 2023
Medical Devices, Infectious Diseases, Defense, Health, Contracts, Duke University, Medicine, U.S. Department of Defense Strategy for Operating in Cyberspace, United States Department of Defense, Respiratory disease, Organic compound, Infection, Volatile organic compound, COVID, Biomarker, Naval Aviation Warfighting Development Center, Exhaled breath condensate, Risk, Vaccine, FAIMS

Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced that it had won an award from the U.S. Defense Innovation Unit (DIU), a division of the U.S. Department of Defense (DoD), for ‘Exhaled Breath Diagnostics’.

Key Points: 
  • Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced that it had won an award from the U.S. Defense Innovation Unit (DIU), a division of the U.S. Department of Defense (DoD), for ‘Exhaled Breath Diagnostics’.
  • The ‘EXHALE’ project, focused on the early detection of human infection using volatile organic compounds (VOCs) on breath, will develop a handheld device capable of non-invasive detection of pre-symptomatic respiratory infectious disease.
  • Warfighters routinely operate in remote environments where access to medical personnel is limited and the ability to diagnose infectious disease early is challenging.
  • The portable device by Owlstone will be adapted to work off battery power and detect VOCs present in exhaled breath, filling a gap in infectious disease detection.

North Louisiana Forensic Science Center to host Cannabix Marijuana Breathalyzer Technology

Retrieved on: 
Thursday, January 5, 2023
UBC, Forensic science, DNA, Fig, THC, FAIMS, Marshall University Forensic Science Center, CSE, OTC, Forensic toxicology, Housing, Firearm, Paraffin wax

In December, Cannabix delivered its MS Breath Sampler instrumentation to the Forensic Science Center in Shreveport, LA.

Key Points: 
  • In December, Cannabix delivered its MS Breath Sampler instrumentation to the Forensic Science Center in Shreveport, LA.
  • Scientists will now be able to confirm THC in breath samples from various field studies at the Forensic Science Center’s state-of-the-art facility.
  • The North Louisiana Criminalistics Laboratory, based in Shreveport, provides forensic science services in the areas of drug chemistry, DNA analysis, firearms examination, and forensic toxicology.
  • Joseph Jones, System Director at the NLCL, stated the following, “We are very pleased to be providing space within the Forensic Science Center for external vendors who are pursuing similar interests to our own efforts towards criminal justice and forensic science.

Cannabix Technologies Participates in New Study with Marijuana Breathalyzer technology – Southern United States

Retrieved on: 
Tuesday, July 12, 2022
Technology, Smoking, THC, NHTSA, News, Company, Regulation, CSI: NY, OTC, CSE, GLOBE, Toxicology, Workplace, Blood, Congress, Mass spectrometry, Urine, Disclosure, FAIMS, Saliva, Growth, Drug

The new study will work along side toxicologists and law enforcement officers in the southern United States.

Key Points: 
  • The new study will work along side toxicologists and law enforcement officers in the southern United States.
  • This kind of study underway in southern United States will provide an important launch point for Cannabix devices in terms of a law enforcement and toxicology audience.
  • Cannabix is using its marijuana breathalyzer technology to detect 9-tetrahydrocannabinol (THC) - the psychoactive component of marijuana that causes impairment, in breath.
  • Cannabix Technologies Inc. is a developer of marijuana breathalyzer technologies for law enforcement and the workplace.

Cannabix Technologies to Present at Breath Summit 2022 - International Association of Breath Research (IABR)

Retrieved on: 
Tuesday, June 7, 2022
CSE, Company, Research, OTC, News, International Association, Regulation, Growth, GLOBE, Technology, FAIMS, Collection, Analyser, Workplace, THC, Personal protective equipment, Breathing

The IABR Breath Summit is one the premier events held globally in relation to breath research.

Key Points: 
  • The IABR Breath Summit is one the premier events held globally in relation to breath research.
  • Cannabix will present its technical expertise in breath aerosol analysis and recent breath testing benchmarks with its FAIMS and THC Breath Analyzer technologies for detection of 9-tetrahydrocannabinol (THC).
  • In addition, Cannabix will present its results from THC analytes captured in human breath performed by an independent experimental study.
  • The study showed excellent correlation between breath samples collected and analyzed with Cannabix hardware and blood plasma levels of THC (see news release dated May 9, 2022).

Cannabix Technologies Correlates THC in Breath and Blood using Proprietary Sample Collection and Analysis Hardware in Experimental Study

Retrieved on: 
Monday, May 9, 2022
Workplace, Data, THC, FAIMS, Cannabinoid, BCU, Woman, Cannabis, GLOBE, Fig, Company, Journal of Analytical Toxicology, Smoking, Plasma, Thermo, Metabolism, CSE, OTC, Literature, Toronto, Blood, Journal, Law enforcement, Formation, The Hospital, Technology, Hospital for Sick Children, Regulation, Growth, AUC, Man, Medical device, Medical imaging

The study showed excellent correlation between breath samples collected and analyzed with Cannabix hardware and blood plasma levels of THC.

Key Points: 
  • The study showed excellent correlation between breath samples collected and analyzed with Cannabix hardware and blood plasma levels of THC.
  • Dr. Olla is one of only a handful of scientists globally who has historically ever conducted THC analysis in blood and breath.
  • 3 below) provides an excellent correlation between human breath samples collected and analyzed with the Cannabix hardware and blood plasma levels of THC.
  • We have developed a truly ground-breaking breath analysis tool capable of breath sampling for THC, within seconds, with no sample preparation needed.

Cannabix Technologies Presents FAIMS Marijuana Breathalyzer Technology at the Texas Impaired Driving Forum

Retrieved on: 
Thursday, February 24, 2022
GLOBE, CSE, Workplace, Method, Growth, Atmospheric pressure, Cannabis, Company, Safety, OTC, Regulation, Mass spectrometry, THC, Policy, FAIMS, Law enforcement, TTI, Technology, Texas A&M Transportation Institute, Mobile phone, Drug

The advent of the Cannabix FAIMS based marijuana breath detection technology comes at a time when legislators across the United States and elsewhere are grappling with the ever-increasing problem of drugged-driving.

Key Points: 
  • The advent of the Cannabix FAIMS based marijuana breath detection technology comes at a time when legislators across the United States and elsewhere are grappling with the ever-increasing problem of drugged-driving.
  • The Texas Impaired Driving Forum attracted attendees from across the state of Texas and elsewhere.
  • Cannabix is using its FAIMS technology to detect THC, a non-volatile compound, in breath.
  • Cannabix Technologies Inc. is a developer of marijuana breathalyzer technologies for law enforcement and the workplace.

Biognosys Expands Co-Marketing Agreement with Global Life Science Leader to Advance Proteomics

Retrieved on: 
Tuesday, December 14, 2021
Health, Medical Devices, Other Science, Research, Science, Pharmaceutical, Biotechnology, Orbitrap, FAIMS, Solution, ASMS, Protein, Company, Proteomics, Data analysis, DIA, Doctor of Philosophy, Co-marketing, Science, Acquisition, Thermo, Thermo Fisher Scientific, Biomarker discovery, West Pharmaceutical Services explosion, Marketing, Proteome, Laboratory, Workflow, Software, Partnership, Senior, Medical imaging, Management, Blood, Health, Medical Devices, Other Science, Research, Science, Pharmaceutical, Biotechnology

The agreement leverages the two companies complementary capabilities in mass spectrometry-based proteomics.

Key Points: 
  • The agreement leverages the two companies complementary capabilities in mass spectrometry-based proteomics.
  • Biognosys deploys Thermo Fisher Scientific instruments in its state-of-the-art facility for contract research services, while Thermo Fisher Scientific co-markets Biognosys software and kits with its Thermo Scientific instruments and workflows.
  • Through the companies extended co-marketing agreement , laboratories with in-house proteomics facilities have access to efficient, accurate, and scalable mass spectrometry-based proteomics workflows combining Thermo Scientific mass spectrometry instruments with Biognosys proteomics data analysis software and kits.
  • Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts.

Cannabix Technologies To Present at Texas Impaired Driving Forum, Provides Corporate Update

Retrieved on: 
Thursday, December 9, 2021
Company, Regulation, Population, GLOBE, Workplace, Health, CSE, Technology, OTC, Cannabis, Pharmacokinetics, Growth, Texas A&M Transportation Institute, UF, Safety, Mass spectrometry, Recreation, FAIMS, THC, Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, Forum, TTI, University, Law enforcement, Medical device, Drug

Cannabixs Dr. Jared Boock, Ph.D., will be presenting the Companys marijuana breathalyzer technologies and approaches at the Forum.

Key Points: 
  • Cannabixs Dr. Jared Boock, Ph.D., will be presenting the Companys marijuana breathalyzer technologies and approaches at the Forum.
  • The 2021 Texas Impaired Driving Forum attracted approximately 300 attendees from across the state of Texas.
  • Cannabix Technologies Inc. is a developer of marijuana breathalyzer technologies for law enforcement and the workplace.
  • There is no assurance that existing patent pending technologies licensed by the Company will receive patent status by regulatory authorities.

Biognosys to Present Major Scientific and Technological Advances at the ASMS 2021 Mass Spectrometry Conference

Retrieved on: 
Thursday, October 21, 2021
Technology, Research, Medical Devices, Software, Biotechnology, Health, Pharmaceutical, Science, Oncology, Lung, Proteomics, Research, Technology, American Society for Mass Spectrometry, Thermo, Deep learning, Workflow, Thermo Fisher Scientific, Annual conferences, Patient, Marketing, Machine learning, FAIMS, Breast, Mass spectrometry, Conference, Senior, Software, ASMS, Protein, Company, Plasma, Solution, Proteome, Immune system, Prostate cancer, Doctor of Philosophy, Society, Vaccine, Medical imaging, Management

Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, today announced they will be presenting major scientific and technological advances on their proprietary proteomics research services, software, and kits at the American Society for Mass Spectrometry (ASMS) Annual Conference from October 31st to November 4th in Philadelphia (USA).

Key Points: 
  • Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, today announced they will be presenting major scientific and technological advances on their proprietary proteomics research services, software, and kits at the American Society for Mass Spectrometry (ASMS) Annual Conference from October 31st to November 4th in Philadelphia (USA).
  • Biognosys will present a record number of 3 oral presentations, 10 scientific posters, 2 poster collaborations, 1 workshop panel, and 2 Spectronaut breakfast seminars.
  • In addition, their team of scientific experts will be present at booth #224 to answer questions and demo software.
  • Biognosys unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput.

Cannabix Achieves New Benchmark for FAIMS Marijuana Breathalyzer Technology

Retrieved on: 
Monday, October 18, 2021
Technology, Atmospheric pressure, CSE, Workplace, Growth, Cannabinoid, OTC, THC, Gold, FAIMS, GLOBE, Company, Regulation, Mass spectrometry, Electronics, Drug

Development of the Cannabix FAIMS drug screen device is aimed primarily for the law enforcement market.

Key Points: 
  • Development of the Cannabix FAIMS drug screen device is aimed primarily for the law enforcement market.
  • Cannabix is using its FAIMS technology to detect 9-tetrahydrocannabinol (THC), a non-volatile compound, in breath.
  • Cannabix Technologies Inc. is a developer of marijuana breathalyzer technologies for law enforcement and the workplace.
  • Cannabix is working to develop drug-screening devices that will detect THC - the psychoactive component of marijuana that causes impairment using breath samples.